Ariceum Therapeutics GmbH announced the acquisition of UK-based Theragnostics Ltd on 1 June giving it a US Food and Drug Administration approved diagnostic and a pipeline of radiolabelled small molecule inhibitors for the treatment of aggressive cancers.
This is the second major business transaction for the German radiopharmaceutical company, which was co-founded in 2021 by venture capital and private equity investors. The first was a peptide-based research collaboration with UCB SA of Belgium, announced on 11 May.